Two brothers had late-onset progressive ataxia, cerebellar atrophy, and hypergonadotropic hypogonadism associated with coenzyme Q10 (CoQ10) deficiency in skeletal muscle. Both patients improved on high-dose CoQ10 supplementation, stressing the importance of CoQ10 deficiency in the differential diagnosis of cerebellar ataxia, even when onset is late.
Patients and methods. Patient 1. This 48-year old man had a normal life until age 39, when he started complaining of progressive dysarthria and problems with balance that made walking difficult. He also had exercise intolerance and cramps. Azoospermia had been identified at age 30, but secondary sexual characteristics and external genitalia were normal.
Neurologic examination showed slow and scanning speech, broken pursuit movements, severe limb ataxia, mild hyperreflexia, and pes cavus bilaterally. Tone and sensation were normal, except for mild impairment of proprioception in the legs. He swayed while standing and was not able to walk Ͼ10 m without some support.
Patient 2.
The 35-year-old brother of Patient 1 was normal until age 29, when azoospermia was documented. One year later, he developed slurred speech and difficulties descending stairs. Three years later, ataxia became evident: He had difficulty walking and fell frequently. Both balance and speech worsened progressively. He had premature fatigue, muscle pain, and cramps.
Neurologic examination was similar to his brother's, but he also had decreased tone and tendon reflexes in all four limbs. Walking was possible without aid, but with considerable staggering and difficulty in turning. He walked slowly and swayed while standing.
There was no consanguinity and no family history of neurologic or endocrine diseases. Five siblings were normal.
Clinical studies. To score the cerebellar dysfunction, we used the International Cooperative Ataxia Rating Scale (ICARS). 10 IC-ARS is a 100-point semiquantitative scale assessing the performance of specific tasks. Compartmentalized quantitations allow one to subscore symptoms and signs related to posture and stance, limb ataxia, dysarthria, and oculomotor dysfunction. The higher the score, the more severe is the cerebellar dysfunction.
The following laboratory tests were normal: vitamin E blood level, CSF analysis, immunologic screening, arylsulfatase A activity, serum lactate and pyruvate, and ophthalmologic evaluation. Neurophysiologic studies showed moderate sensory-motor neuropathy of mixed axonal-demyelinating type (30% decrease of motor conduction velocity and 60% decrease of compound motor action potential); sensory evoked potentials of the median and tibial nerves were slightly slowed and had moderately decreased amplitudes.
Brainstem auditory evoked potentials disclosed slightly reduced but not delayed responses. Audiology showed mild sensorineural deafness.
Neuropsychological tests in Patient 1 showed moderate deficit in constructional praxis, long-term memory, and visuospatial short-term memory; in Patient 2, there was a mild decrease of executive function and visuospatial short-term memory. Brain MRI showed atrophy of the cerebellum and pons. Neurologic examination and sensory-motor conduction studies were normal in the other five siblings (two men and three women) and in the mother.
Endocrinologic testing in Patient 1 showed the following values: testosterone 2.8 ng/mL (normal 2.90 to 8.00 ng/mL), luteinizing hormone (LH) 18.9 mIU/mL (normal 1.7 to 8.6 mIU/mL), and follicle-stimulating hormone (FSH) 27 IU/mL (normal 0.9 to 18 IU/mL). In Patient 2, the values were as follows: testosterone 2.1 ng/mL (normal 2.90 to 8.00 ng/mL), LH 11.8 mIU/mL (normal 1.7 to 8.6 mIU/mL), and FSH 22.1 IU/mL (normal 0.9 to 18 IU/mL).
Prolactin, free thyroxine 3, free thyroxine 4, thyroidstimulating hormone, adrenocorticotropic hormone, and cortisol were normal in both patients.
Results and discussion. Muscle biopsies showed mild neurogenic changes in both patients. The activities of respiratory chain complexes were normal, and analyses of mitochondrial DNA showed no large-scale rearrangements and none of the common pathogenic point mutations. Genetic analyses for Friedreich ataxia and for spinocerebellar atrophy-1, 2, 4, and 6 were also normal.
The concentration of CoQ10 in muscle (measured by reverse-phase high-performance liquid chromatography) 4 was 15.8 g/g of fresh tissue in Patient 1 and 13.5 g/g in Patient 2. These values were below 2 SD of the mean CoQ10 concentration in 121 normal muscle specimens (27.6 Ϯ 4.4 g/g) and fell at or below the cutoff value (15 g/g of fresh tissue) chosen to define primary CoQ10 deficiency in muscle. 5 Both patients were started on oral CoQ10 supplementation (Ubimaior, kindly provided by Chiesi Pharmaceuticals, Parma, Italy): Patient 1 (weight 86 kg) on 1,200 mg daily and Patient 2 (weight 69 kg) on 750 mg daily.
The patients were evaluated before therapy and after 2, 3, and 5 months of therapy. Both showed improved postural stability, gait, and speech articulation, which were reflected by the ICARS scores (table). There were no adverse events related to CoQ10 supplementation.
After 2 months of therapy, brain MRI were unchanged. Neurophysiologic tests showed mild increases of motor action potentials in the ulnar (from 13.7 to 16.3 mV) and external sciatic-popliteus (from 4.6 to 6.5 mV) nerves in Patient 2, but no changes in Patient 1. Endocrinologic assays showed that testosterone levels had returned to the normal range in both patients (6.4 ng/mL in Patient 1 and 3.5 ng/mL in Patient 2).
Neuropsychological evaluation 3 months after therapy disclosed considerable improvements in memory tasks.
Ubiquinone or CoQ10 is a lipophilic component of the electron transport chain, which transfers reducing equivalents from complex I and II to complex III. CoQ10 in its reduced form also plays a role as an antioxidant and as a membrane stabilizer.
The association of familial cerebellar ataxia and hypogonadism was first noted almost a century ago by Holmes. 9 Whereas most patients have hypogonadotropic hypogonadism, 15 patients with hypergonadotropic hypogonadism have been reported. 9 These patients have an autosomal recessive disorder not due to mutations in the frataxin gene and often associated with other neurologic symptoms such as peripheral neuropathy and neurosensory hearing loss, as in our patients. As these clinical features mimic those described in the ataxic form of CoQ10 deficiency, we measured CoQ10 in muscle from our patients. We found that CoQ10 was, in fact, markedly decreased, suggesting that this syndrome is a variant of the ataxic presentation, with two distinguishing characteristics: the late onset of ataxia and the association of hypergonadotropic hypogonadism. Among the 15 reported cases with cerebellar ataxia and hypergonadotropic hypergonadism, 9 there was considerable heterogeneity in age at onset, severity, rate of progression, and associated abnormalities. However, all but one case had onset before age 20, unlike our patients, who showed the first signs of ataxia at ages 30 and 39.
Similar to all other cases of primary CoQ10 deficiency, our patients showed some improvement after initiating high-dose CoQ10 supplementation. As documented by IC-ARS scores, the improvement was continuing at the 5-month follow-up.
The molecular bases and pathogenetic mechanisms of the various presentations of primary CoQ10 deficiency remain to be elucidated. The biosynthesis of CoQ10 is complex, and blocks at different sites could explain the different phenotypes associated with primary CoQ10 deficiency. As the synthesis of steroid hormones starts with cholesterol, which has the same biosynthetic pathway as CoQ10, it is not inconceivable that CoQ10 and testosterone deficiencies may coexist. Unfortunately, endocrine studies were not performed in previously described patients with the ataxic form of CoQ10 deficiency, most of whom were children. 4, 5 CoQ10 deficiency should be considered in the differential diagnosis of all undefined childhood-and adult-onset cases of cerebellar ataxia, not only because the clinical spectrum of this disorder keeps expanding, but also because CoQ10 administration seems to improve some cerebellar symptoms and-perhaps more markedly-some of the associated conditions.
